Several other research analysts have also weighed in on HIK. Morgan Stanley reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, November 13th. Barclays reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a report on Thursday, February 20th. HSBC reiterated a “reduce” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, November 27th. Citigroup reiterated a “neutral” rating on shares of Hikma Pharmaceuticals in a report on Friday. Finally, Jefferies Financial Group reduced their target price on Hikma Pharmaceuticals from GBX 2,310 ($30.39) to GBX 2,240 ($29.47) and set a “buy” rating on the stock in a report on Tuesday, January 21st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of GBX 1,853.33 ($24.38).
HIK stock opened at GBX 1,832 ($24.10) on Friday. The business’s 50-day moving average price is GBX 1,904.54 and its two-hundred day moving average price is GBX 1,964.26. The company has a current ratio of 1.28, a quick ratio of 0.78 and a debt-to-equity ratio of 37.69. The firm has a market cap of $4.63 billion and a PE ratio of 12.31. Hikma Pharmaceuticals has a 1-year low of GBX 16.58 ($0.22) and a 1-year high of GBX 2,089.19 ($27.48).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Featured Article: What sectors are represented in the Nikkei Index?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.